Sandoz Reveals Aflibercept Program

Kicks Off Phase III Trials For Biosimilar Version Of Eylea

 
• By David Wallace
  
Eye Scan Data
Sandoz is enrolling patients for an aflibercept trial • Source: Alamy

More from Biosimilars

More from Products